Skip to main content
Figure 3 | BMC Cancer

Figure 3

From: Redox-responsive targeted gelatin nanoparticles for delivery of combination wt-p53 expressing plasmid DNA and gemcitabine in the treatment of pancreatic cancer

Figure 3

In vivo anti-tumor activity of gemcitabine conjugated gelatin nanoparticles. (a) Volume change as a function of time showing 39.4*, 50.7** and 61.7%*** reduction in tumor growth on day 33 for Gem-Gel, Gem-Gel-PEG and Gem-Gel-PEG-peptide nanoparticle treated tumor respectively. (b) Tumor weights were measured at day 33. Results are presented as mean ± SD (n = 6; *p < 0.05; **p < 0.01; ***p < 0.001).

Back to article page